-
公开(公告)号：US20100135998A1
公开(公告)日：2010-06-03
申请号：US12527459
申请日：2008-02-26
申请人： Edward Paul Bowman , Daniel J. Cua , Robert A. Kastelein , Kathy Lynn Miller , Melanie A. Kleinschek , Kristian S. Bak-Jensen , Katia Boniface , Brent S. McKenzie , Rene de Waal Malefyt
发明人： Edward Paul Bowman , Daniel J. Cua , Robert A. Kastelein , Kathy Lynn Miller , Melanie A. Kleinschek , Kristian S. Bak-Jensen , Katia Boniface , Brent S. McKenzie , Rene de Waal Malefyt
CPC分类号： A61K39/3955 , A61K31/55 , A61K31/5575 , A61K38/1793 , A61K39/395 , A61K45/06 , C07K16/244 , C07K2317/76 , A61K2300/00
摘要： Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
摘要翻译： 提供了用于治疗诸如自身免疫性疾病或癌症的免疫疾病的方法和组合，涉及与抑制Th17细胞发育或维持的药物的联合治疗。 提供了治疗方案，其中施用促炎细胞因子的拮抗剂足以缓解自身免疫性疾病或癌症的急性期急性发作的体征和症状，并且用IL-23拮抗剂治疗是 持续较长时间，以防止急性事件复发。 还公开了PGE2和CD161的拮抗剂用于治疗自身免疫性，炎性和增殖性疾病。
-
公开(公告)号：US20120156699A1
公开(公告)日：2012-06-21
申请号：US13405024
申请日：2012-02-24
申请人： Edward P. Bowman , Daniel J. Cua , Robert A. Kastelein , Kathy Lynn Miller , Melanie A. Kleinschek , Katia Boniface , Kristian S. Bak-Jensen , Brent S. McKenzie , Rene de Waal Malefyt
发明人： Edward P. Bowman , Daniel J. Cua , Robert A. Kastelein , Kathy Lynn Miller , Melanie A. Kleinschek , Katia Boniface , Kristian S. Bak-Jensen , Brent S. McKenzie , Rene de Waal Malefyt
IPC分类号： G01N33/566 , C07K16/46
CPC分类号： A61K39/3955 , A61K31/55 , A61K31/5575 , A61K38/1793 , A61K39/395 , A61K45/06 , C07K16/244 , C07K2317/76 , A61K2300/00
摘要： Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
摘要翻译： 提供了用于治疗诸如自身免疫性疾病或癌症的免疫疾病的方法和组合，涉及与抑制Th17细胞发育或维持的药物的联合治疗。 提供了治疗方案，其中施用促炎细胞因子的拮抗剂足以缓解自身免疫性疾病或癌症的急性期急性发作的体征和症状，并且用IL-23拮抗剂治疗是 持续较长时间，以防止急性事件复发。 还公开了PGE2和CD161的拮抗剂用于治疗自身免疫性，炎性和增殖性疾病。
-
3.发明授权Compositions for enhancing keratinocyte migration and epidermal repair via a receptor containing OSMRβ as a subunit, and applications thereof 有权用于通过含有OSMR和bgr的受体增强角质形成细胞迁移和表皮修复的组合物 作为亚基，及其应用公开(公告)号：US07901669B2
公开(公告)日：2011-03-08
申请号：US11721888
申请日：2005-12-15
申请人： Jean-Claude Lecron , Hughes Gascan , Franck Morel , Sylvie Chevalier , François-Xavier Bernard , Katia Boniface , Caroline Diveu
发明人： Jean-Claude Lecron , Hughes Gascan , Franck Morel , Sylvie Chevalier , François-Xavier Bernard , Katia Boniface , Caroline Diveu
CPC分类号： A61K8/64 , A61K38/1793 , A61K38/20 , A61K38/204 , A61K38/217 , A61Q19/00 , C07K16/28 , C07K2317/76 , C12N5/0629 , C12N2501/2306 , A61K2300/00
摘要： The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to activate a heteromeric receptor comprising OSMRβ as a subunit, for the preparation of a composition for activating in vitro and/or in vivo keratinocyte migration and/or the expression of anti-microbial peptides by the keratinocytes. In particular, the invention concerns the use of OSM and/or IL-17 and/or TNFα and/or IL-31, or agonists thereof, for the preparation of cosmetic or dermatologic compositions.
摘要翻译： 本发明涉及表皮修复领域。 更具体地，本发明涉及能够激活包含OSMR和bgr的异聚受体的分子的用途。 作为亚单位，用于制备用于激活角质形成细胞的体外和/或体内角质形成细胞迁移和/或抗微生物肽的表达的组合物。 特别地，本发明涉及用于制备化妆品或皮肤病学组合物的OSM和/或IL-17和/或TNFα和/或IL-31或其激动剂的用途。
-
4.发明申请COMPOSITIONS AND METHODS FOR ENHANCING EPIDERMAL REPAIR AND CUTANEOUS INNATE IMMUNITY 审中-公开用于增强腹膜修复和切除性免疫缺陷的组合物和方法公开(公告)号：US20150086508A1
公开(公告)日：2015-03-26
申请号：US14500373
申请日：2014-09-29
申请人： Jean-Claude Lecron , Hughes Gascan , Franck Morel , Sylvie Chevalier , Francois-Xavier Bernard , Katia Boniface , Caroline Diveau
发明人： Jean-Claude Lecron , Hughes Gascan , Franck Morel , Sylvie Chevalier , Francois-Xavier Bernard , Katia Boniface , Caroline Diveau
CPC分类号： A61K38/2006 , A61K8/64 , A61K38/1793 , A61K38/20 , A61K38/204 , A61K38/217 , A61Q19/00 , C07K16/28 , C07K2317/76 , C12N5/0629 , C12N2501/2306 , A61K2300/00
摘要： The invention disclosed herein relates to the field of epidermal repair and skin innate immunity. More particularly, the invention concerns the use of a mix of cytokines to inhibit keratinocyte differentiation, activate skin innate immunity, increase the expression of anti-microbial peptides, and improve epidermal repair. In particular, the invention concerns compositions comprising at least IL-17, TNFα and OSM that can be formulated for topical administration for cosmetic or dermatologic use.
摘要翻译： 本文公开的本发明涉及表皮修复和皮肤先天免疫领域。 更具体地，本发明涉及细胞因子混合物用于抑制角质形成细胞分化，激活皮肤先天免疫，增加抗微生物肽表达以及改善表皮修复的用途。 特别地，本发明涉及至少包含IL-17，TNFα和OSM的组合物，其可以配制用于化妆品或皮肤病学用途的局部给药。
-
5.发明申请COMPOSITIONS FOR PREVENTING, REDUCING OR TREATING KERATINOCYTE-MEDIATED INFLAMMATION 审中-公开用于预防，减少或治疗杀伤细胞介导性感染的组合物公开(公告)号：US20120142755A1
公开(公告)日：2012-06-07
申请号：US13283508
申请日：2011-10-27
申请人： Jean-Claude Lecron , Hughes Gascan , Franck Morel , Sylvie Chevalier , François-Xavier Bernard , Katia Boniface , Caroline Diveu
发明人： Jean-Claude Lecron , Hughes Gascan , Franck Morel , Sylvie Chevalier , François-Xavier Bernard , Katia Boniface , Caroline Diveu
IPC分类号： A61K31/713 , A61P17/00 , A61P29/00 , A61P17/06 , A61P17/12
CPC分类号： A61K8/64 , A61K38/1793 , A61K38/20 , A61K38/204 , A61K38/217 , A61Q19/00 , C07K16/28 , C07K2317/76 , C12N5/0629 , C12N2501/2306 , A61K2300/00
摘要： The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to inhibit a heteromeric receptor comprising OSMRβ as a subunit, for the preparation of a composition for inhibiting the expression of inflammatory factors by the keratinocytes. In particular, the invention concerns the use of antagonists and/or expression inhibitors of OSM, IL-17, TNFα, IL-31, IFN-γ, and/or the OSMRβ subunit, for the preparation of cosmetic or dermatologic compositions, especially for treating inflammatory skin diseases.Methods for obtaining in vitro or animal models of skin inflammation diseases are also disclosed. These models can be used for screening molecules to find new drugs to prevent or treat psoriasis and other dermatitis.
摘要翻译： 本发明涉及表皮修复领域。 更具体地，本发明涉及能够抑制包含OSMR和bgr的异聚受体的分子的用途。 作为亚单位，用于制备用于抑制角质形成细胞表达炎症因子的组合物。 特别地，本发明涉及OSM，IL-17，TNFα，IL-31，IFN-γ和/或OSMR＆bgr的拮抗剂和/或表达抑制剂的用途。 亚单位，用于制备化妆品或皮肤病学组合物，特别是用于治疗炎性皮肤疾病。 还公开了用于获得皮肤炎症疾病的体外或动物模型的方法。 这些模型可用于筛选分子，以寻找新药来预防或治疗牛皮癣和其他皮炎。
-
公开(公告)号：US10080779B2
公开(公告)日：2018-09-25
申请号：US14500373
申请日：2014-09-29
申请人： Jean-Claude Lecron , Hughes Gascan , Franck Morel , Sylvie Chevalier , Francois-Xavier Bernard , Katia Boniface , Caroline Diveau
发明人： Jean-Claude Lecron , Hughes Gascan , Franck Morel , Sylvie Chevalier , Francois-Xavier Bernard , Katia Boniface , Caroline Diveau
IPC分类号： A61K38/19 , A61K38/20 , A61K38/17 , A61K38/21 , A61K8/64 , A61Q19/00 , C07K16/28 , C12N5/071
CPC分类号： A61K38/2006 , A61K8/64 , A61K38/1793 , A61K38/20 , A61K38/204 , A61K38/217 , A61Q19/00 , C07K16/28 , C07K2317/76 , C12N5/0629 , C12N2501/2306 , A61K2300/00
摘要： The invention disclosed herein relates to the field of epidermal repair and skin innate immunity. More particularly, the invention concerns the use of a mix of cytokines to inhibit keratinocyte differentiation, activate skin innate immunity, increase the expression of anti-microbial peptides, and improve epidermal repair. In particular, the invention concerns compositions comprising at least IL-17, TNFα and OSM that can be formulated for topical administration for cosmetic or dermatologic use.
-
7.发明申请COMPOSITIONS FOR PREVENTING, REDUCING OR TREATING KERATINOCYTE-MEDIATED INFLAMMATION 审中-公开用于预防，减少或治疗杀伤细胞介导性感染的组合物公开(公告)号：US20090300776A1
公开(公告)日：2009-12-03
申请号：US11721763
申请日：2005-12-15
申请人： Jean-Claude Lecron , Hughes Gascan , Franck Morel , Sylvie Chevalier , Francois-Xavier Bernard , Katia Boniface , Caroline Diveu
发明人： Jean-Claude Lecron , Hughes Gascan , Franck Morel , Sylvie Chevalier , Francois-Xavier Bernard , Katia Boniface , Caroline Diveu
CPC分类号： A61K8/64 , A61K38/1793 , A61K38/20 , A61K38/204 , A61K38/217 , A61Q19/00 , C07K16/28 , C07K2317/76 , C12N5/0629 , C12N2501/2306 , A61K2300/00
摘要： The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to inhibit a heteromeric receptor comprising OSMRβ as a subunit, for the preparation of a composition for inhibiting the expression of inflammatory factors by the keratinocytes. In particular, the invention concerns the use of antagonists and/or expression inhibitors of OSM, IL-17, TNFα, IL-31, IFN-γ, and/or the OSMRβ subunit, for the preparation of cosmetic or dermatologic compositions, especially for treating inflammatory skin diseases.Methods for obtaining in vitro or animal models of skin inflammation diseases are also disclosed. These models can be used for screening molecules to find new drugs to prevent or treat psoriasis and other dermatitis.
摘要翻译： 本发明涉及表皮修复领域。 更具体地，本发明涉及能够抑制包含OSMRbeta作为亚单位的异聚受体的分子在制备用于抑制角质形成细胞表达炎性因子的组合物中的应用。 特别地，本发明涉及用于制备化妆品或皮肤病学组合物的OSM，IL-17，TNFα，IL-31，IFN-γ和/或OSMRbeta亚基的拮抗剂和/或表达抑制剂的用途， 治疗炎症性皮肤病。 还公开了用于获得皮肤炎症疾病的体外或动物模型的方法。 这些模型可用于筛选分子，以寻找新药来预防或治疗牛皮癣和其他皮炎。
-
8.发明申请COMPOSITIONS FOR ENHANCING KERATINOCYTE MIGRATION AND EPIDERMAL REPAIR VIA A RECEPTOR CONTAINING OSMRBETA AS A SUBUNIT, AND APPLICATIONS THEREOF 有权用于增强包含OSMRBETA亚纲的受体的KERATINOCYTE MIGRATION和EPIDERMAL REPAIR的组合物及其应用公开(公告)号：US20090104146A1
公开(公告)日：2009-04-23
申请号：US11721888
申请日：2005-12-15
申请人： Jean-Claude Lecron , Hughes Gascan , Franck Morel , Sylvie Chevalier , Francois-Xavier Bernard , Katia Boniface , Caroline Diveu
发明人： Jean-Claude Lecron , Hughes Gascan , Franck Morel , Sylvie Chevalier , Francois-Xavier Bernard , Katia Boniface , Caroline Diveu
CPC分类号： A61K8/64 , A61K38/1793 , A61K38/20 , A61K38/204 , A61K38/217 , A61Q19/00 , C07K16/28 , C07K2317/76 , C12N5/0629 , C12N2501/2306 , A61K2300/00
摘要： The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to activate a heteromeric receptor comprising OSMRβ as a subunit, for the preparation of a composition for activating in vitro and/or in vivo keratinocyte migration and/or the expression of anti-microbial peptides by the keratinocytes. In particular, the invention concerns the use of OSM and/or IL-17 and/or TNFα and/or IL-31, or agonists thereof, for the preparation of cosmetic or dermatologic compositions.
摘要翻译： 本发明涉及表皮修复领域。 更具体地，本发明涉及使用能够激活包含OSMRbeta作为亚单位的异聚受体的分子，用于制备用于在体外和/或体内角化细胞迁移和/或抗微生物肽表达的活化组合物 由角质形成细胞。 特别地，本发明涉及用于制备化妆品或皮肤病学组合物的OSM和/或IL-17和/或TNFα和/或IL-31或其激动剂的用途。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.044 秒)
